Good grief the worst thing he pointed out was the side effects. That should have instantly taken it below 3. For a sane biotech investor, why is there no focus on that? Shouldn't be investing in biotech if you don't understand the importance.
SRI tested extensively under much better clinical trial showed no effect so there is a better basis for extrapolation of whether experimental work will translate in the clinic. It makes any claims by AVXL much more dubious.
Five weeks? Does the brain work by repairing the cells or re-wiring the brain after it's damaged? Is it that the misfolded proteins short or suppress signaling in the brain? Is it even likely that the brain would repair itself in five weeks?I don't know how they can make their claims against the background, but it seems unlikely that the brain repairs itself this quickly in an observable fashion.
I put in an order for AVXL at 1.25 this morning and will play it only technically from here on out. Also hoping I get most dislikes today.
Will probably head back to 33
Companies on the level don't comment on rumors most of the time. So that's a neutral for the most part.
The articles indicated that SHPG was in talks with three banks to find financing. The specificity of the report was the only thing that indicated to me it was accurate. Otherwise how rare is it for people to be able to get in? If it goes down to 30, we can expect a 50% or more increase, although I'll buy most of mine at 33 because i don't expect it to go past that seeing as how it has some binaries coming up.
I'm just saying that the article seems more like something that a hedgie passed so they could get out of the stock. It's done all the time and it's probably the only way someone could get out quickly.
Speaking of the binaries anyone care to guess BXLT price range upon success and failure of each event?
Study, Scheduled to Begin in 2016, Will Represent First Clinical Application of In Vivo Genome Editing
PR Newswire Sangamo BioSciences, Inc.
7 hours ago
RICHMOND, Calif., Dec. 1, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-FIX, a potentially curative, single treatment therapy for hemophilia B. SB-FIX is the first in vivo genome editing application to enter the clinic and is based on Sangamo's proprietary In Vivo Protein Replacement Platform™ (IVPRP™). The IND is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-FIX-1501) designed to assess safety, tolerability and potential efficacy of SB-FIX in adults with hemophilia B.
There is no doubt that Shire is trying to acquire BXLT. They said so in the presentation. Doesn't look like I'm going to get shares at 33.
Very possibly the thread above alerting retailers like myself that they are definetely pursuing BXLT:
Shire Presentation at Piper Jaffray Conference
Dec 1, 2015 4:02 PM
Anybody want to lay out a thesis on the price of the takeout? I'll go with 300 per share so people can claim to be conservative when they say 70 to 100 per share.
it would be nice to see 48-50, but I can't formulate a valuation.
gnoring hides all Finance Message Boards posts made by a user.
Ignoring a user - while viewing a Message Boards post, click Flag | Ignore User.
Unignoring a user - on an ignored Message Boards post, click Flag | UnIgnore User.
Note - Once you have 100 users in your ignore list, you won't be able to ignore more users. You'll know if you reach the limit because you'll receive this message: "Error: Your ignore list is full (maximum 100)"
It's the opposite of what the retailer expects isn't it? They make their most money that way. Could be second leg down of biotech rout. Economy crash coming. I loaded up so not a good sign.
Dude read some of the threads. I already posted twice saying that it was true that BXLTA was being pursued by SHPG and a mea culpa of sorts. Glad you're the super nova enlightening us all a day late. I even posited that the thread mentioning the piper jaffrey conference might have had something to do with the bump yesterday.
When we see the volume pick up or a price over 40 then we'll know something serious is about to happen. Until then the news article doesn't appear to be announcing anything the investing community didn't already know. So it was likely still a news release to get the retailer's money.
Anyway since BXLTA will see growth and it is being pursued by SHPG it seems like a no brainer.
SInce you're so studious and do so much research, you must have figured out the takeout value. Don't be a dope share it with us.
There is also end of the year selling for taxes that seems to happen this time of year. A possible rotation out of biotech. Not too long ago, cancer immunotherapy stocks were for the most part approaching overbought. it could be sell on the news, most news is out for awhile. Numerous parameters are always present that can over rule the logical direction of a stock.
They brought it down before ASH. It certainly is less than a sure thing, but it more likely to go up if brought down.
One other thing, if the consensus result in solid tumors is that there are poor or no results, it would be a bonfide reason for the sell off.
Relypsa is interesting as a buy out, even after it has gone up. Unfortunately all my shares had covered calls. Black box warning means nothing towards drug's use. I don't think anything serious is occurring but if it settles down people might want to check it out as takeout is 40 and maybe as high as 70. What the companies said:
I want to emphasize at this point that this is just a rumor, as a representative from Relypsa declined to comment on the situation. Merck also declined to comment, and neither company has issued a press release on the situation.